Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC11FCD in recurrent glioblastoma
NCT04657315Phase 2Completed
- Sponsor
- CHA University
- Start
- Jun 2020
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MSC11FCD in glioblastoma (GBM), sponsored by CHA University. Started Jun 2020; status: completed.
02
Drugs
MSC11FCD
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04657315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04657315.